Pay in 4 interest-free payments of $7.01 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
Some of these capability packages require products to meet CNSA Suite cryptographic requirements
3 RGN-259 Phase 3 Trial in Neurotrophic Keratopathy Sosne et al., International Journal of Molecular Sciences (2022) This Phase 3 randomized, placebo-controlled, double-masked clinical trial evaluated topical 0.1% RGN-259 (full-length recombinant T4 ophthalmic solution) in patients with neurotrophic keratopathy
25 this seemingly contradictory finding by reporting that the BChE activity is higher in people with UD and BD compared to controls
Intravenous glutathione achieves near-100% bioavailability by delivering GSH directly into the bloodstream
US$ 24.38
US$ 28.95
US$ 24.18
US$ 25.91
